

Dossier zur Nutzenbewertung gemäß § 35a SGB V

Fruquintinib (FRUZAQLA®)

Takeda GmbH

Modul 4 A, Anhang 4-G

Behandlung von Patienten mit metastasierendem Kolorektalkarzinom (mCRC), die zuvor mit verfügbaren Standardtherapien, einschließlich Fluoropyrimidin-, Oxaliplatin- und Irinotecan-basierten Chemotherapien, Anti-VEGF-Arzneimitteln und Anti-EGFR- Arzneimitteln, behandelt wurden und bei denen die Erkrankung unter Behandlung mit Trifluridin-Tipiracil oder Regorafenib fortgeschritten ist, oder die diese Behandlung nicht vertragen

Zusatzanalysen

Stand: 03.06.2024


Inhaltsverzeichnis

Studie FRESCO-2, Zusatzanalysen

1. ITT-Population
 - 1.1. Analysen Tumoransprechen
 - 1.2. Analysen Allgemeiner Gesundheitszustand
 - 1.2.1. Rücklaufquote EQ-5D VAS
 - 1.2.2. Responderanalyse – Zeit bis zur 1. Verschlechterung um ≥ 15 Punkte oder Tod
 - 1.2.3. Responderanalyse – Zeit bis zur 1. Verschlechterung um ≥ 15 Punkte
 - 1.2.4. Responderanalyse – Zeit bis zur 1. Verbesserung um ≥ 15 Punkte
 - 1.2.5. MMRM-Analyse
 - 1.3. Analysen Symptomatik und gesundheitsbezogene Lebensqualität (EORTC QLQ-C30)
 - 1.3.1. Rücklaufquote EORTC QLQ-C30
 - 1.3.2. Responderanalyse – Zeit bis zur 1. Verschlechterung um ≥ 10 Punkte oder Tod
 - 1.3.3. Responderanalyse – Zeit bis zur 1. Verschlechterung um ≥ 10 Punkte
 - 1.3.4. Responderanalyse – Zeit bis zur 1. Verbesserung um ≥ 10 Punkte
 - 1.3.5. MMRM-Analyse
 - 1.4. Q-TWiST-Analyse
2. Sicherheitspopulation
 - 2.1. Sicherheitsanalysen
 - 2.1.1. UE-Gesamtraten
 - 2.1.2. UE-Gesamtraten (ohne erkrankungsbezogene Ereignisse)
 - 2.1.3. UE auf SOC-/PT-Level
 - 2.1.4. UE des NCI CTCAE-Grads ≥ 3 auf SOC-/PT-Level
 - 2.1.5. Schwerwiegende UE auf SOC-/PT-Level
 - 2.1.6. AESI
 - 2.1.7. AESI des NCI CTCAE-Grads ≤ 2
 - 2.1.8. AESI des NCI CTCAE-Grads ≥ 3
 - 2.1.9. Schwerwiegende AESI
3. Endpunktspezifische Nachbeobachtungszeiten
4. Subgruppen
 - 4.1. Interaktionstests
 - 4.2. Analysen
 - 4.2.1. Gesamtüberleben
 - 4.2.2. Progressionsfreies Überleben
 - 4.2.3. Allgemeiner Gesundheitszustand (EQ-5D VAS)
 - 4.2.4. Symptomatik und gesundheitsbezogene Lebensqualität (EORTC QLQ-C30)
 - 4.2.5. Q-TWiST
 - 4.2.6. Sicherheit


4.2.6 Sicherheit

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Nervous system disorders** and Preferred Term **Dysgeusia**
 <=3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Nervous system disorders** and Preferred Term **Dizziness**
 <=3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Renal and urinary disorders**
 ≤3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Renal and urinary disorders** and Preferred Term **Proteinuria**
 <=3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Renal and urinary disorders** and Preferred Term **Haematuria**
 <=3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Infections and infestations**
 <=3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Infections and infestations** and Preferred Term **Urinary tract infection**
 <=3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Infections and infestations** and Preferred Term **COVID-19**
 <=3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Blood and lymphatic system disorders**
 ≤3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Blood and lymphatic system disorders** and Preferred Term **Anaemia**
 <=3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Blood and lymphatic system disorders** and Preferred Term **Thrombocytopenia**
 <=3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Endocrine disorders**
 ≤3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Endocrine disorders** and Preferred Term **Hypothyroidism**
 <=3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Psychiatric disorders**
 <=3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Psychiatric disorders** and Preferred Term **Insomnia**
 <=3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Psychiatric disorders** and Preferred Term **Anxiety**
 <=3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Psychiatric disorders** and Preferred Term **Confusional state**
 <=3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Hepatobiliary disorders**
 <=3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Hepatobiliary disorders** and Preferred Term **Hypertransaminasaemia**
 <=3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Hepatobiliary disorders** and Preferred Term **Hyperbilirubinaemia**
 <=3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Asthenia**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Fatigue**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Pyrexia**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Mucosal inflammation**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Oedema peripheral**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **General physical health deterioration**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Condition aggravated**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Chills**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Diarrhoea**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Nausea**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Abdominal pain**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Constipation**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Vomiting**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Stomatitis**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Abdominal pain upper**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Proctalgia**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Dry mouth**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Ascites**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Dyspepsia**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Decreased appetite**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypokalaemia**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hyponatraemia**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hyperuricaemia**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypoalbuminaemia**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypomagnesaemia**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Dehydration**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hyperglycaemia**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypertriglyceridaemia**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypophosphataemia**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Investigations**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Weight decreased**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Aspartate aminotransferase increased**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Alanine aminotransferase increased**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood bilirubin increased**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood thyroid stimulating hormone increased**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood alkaline phosphatase increased**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Platelet count decreased**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood creatinine increased**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Amylase increased**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Lipase increased**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Dysphonia**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Dyspnoea**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Cough**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Epistaxis**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Oropharyngeal pain**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Vascular disorders**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Vascular disorders** and Preferred Term **Hypertension**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Back pain**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Arthralgia**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Pain in extremity**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Myalgia**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Musculoskeletal chest pain**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Muscle spasms**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Palmar-plantar erythrodysesthesia syndrome**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Rash**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Dry skin**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Nervous system disorders**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Nervous system disorders** and Preferred Term **Headache**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Nervous system disorders** and Preferred Term **Dysgeusia**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Nervous system disorders** and Preferred Term **Dizziness**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Renal and urinary disorders**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Renal and urinary disorders** and Preferred Term **Proteinuria**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Renal and urinary disorders** and Preferred Term **Haematuria**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Infections and infestations**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Infections and infestations** and Preferred Term **Urinary tract infection**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Infections and infestations** and Preferred Term **COVID-19**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Infections and infestations** and Preferred Term **Pneumonia**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Blood and lymphatic system disorders**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Blood and lymphatic system disorders** and Preferred Term **Anaemia**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Blood and lymphatic system disorders** and Preferred Term **Thrombocytopenia**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Endocrine disorders**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Endocrine disorders** and Preferred Term **Hypothyroidism**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Psychiatric disorders**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Psychiatric disorders** and Preferred Term **Insomnia**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Psychiatric disorders** and Preferred Term **Anxiety**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Psychiatric disorders** and Preferred Term **Confusional state**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Hepatobiliary disorders**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE in SOC Term **Hepatobiliary disorders** and Preferred Term **Hypertransaminasaemia**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Asthenia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Fatigue**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Pyrexia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Mucosal inflammation**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 Yes



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Oedema peripheral**
 Yes



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population

TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **General physical health deterioration**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Condition aggravated**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Chills**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Diarrhoea**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Nausea**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Abdominal pain**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Constipation**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Vomiting**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Stomatitis**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Abdominal pain upper**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Proctalgia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Dry mouth**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Ascites**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Dyspepsia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Decreased appetite**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypokalaemia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hyponatraemia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hyperuricaemia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypoalbuminaemia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypomagnesaemia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Dehydration**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hyperglycaemia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypertriglyceridaemia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypophosphataemia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Investigations**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Weight decreased**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Aspartate aminotransferase increased**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Alanine aminotransferase increased**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood bilirubin increased**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood thyroid stimulating hormone increased**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood alkaline phosphatase increased**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Platelet count decreased**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood creatinine increased**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Amylase increased**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Lipase increased**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Dysphonia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Dyspnoea**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Cough**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Epistaxis**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Oropharyngeal pain**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Vascular disorders**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Vascular disorders** and Preferred Term **Hypertension**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Back pain**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Arthralgia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Pain in extremity**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Myalgia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Musculoskeletal chest pain**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Muscle spasms**
 Yes



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders**
 Yes



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population

TEAE in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Palmar-plantar erythrodysesthesia syndrome**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Rash**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Dry skin**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Nervous system disorders**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Nervous system disorders** and Preferred Term **Headache**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Nervous system disorders** and Preferred Term **Dysgeusia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Nervous system disorders** and Preferred Term **Dizziness**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Renal and urinary disorders**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Renal and urinary disorders** and Preferred Term **Proteinuria**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Renal and urinary disorders** and Preferred Term **Haematuria**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Infections and infestations**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Infections and infestations** and Preferred Term **Urinary tract infection**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Infections and infestations** and Preferred Term **COVID-19**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Infections and infestations** and Preferred Term **Pneumonia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Blood and lymphatic system disorders**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Blood and lymphatic system disorders** and Preferred Term **Anaemia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Blood and lymphatic system disorders** and Preferred Term **Thrombocytopenia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Endocrine disorders**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Endocrine disorders** and Preferred Term **Hypothyroidism**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Psychiatric disorders**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Psychiatric disorders** and Preferred Term **Insomnia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Psychiatric disorders** and Preferred Term **Anxiety**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Psychiatric disorders** and Preferred Term **Confusional state**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Hepatobiliary disorders**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Hepatobiliary disorders** and Preferred Term **Hypertransaminasaemia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Hepatobiliary disorders** and Preferred Term **Hyperbilirubinaemia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Asthenia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Fatigue**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Pyrexia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Mucosal inflammation**
 No



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 No



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population

TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **General physical health deterioration**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Diarrhoea**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Nausea**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Abdominal pain**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Constipation**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Vomiting**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Stomatitis**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Abdominal pain upper**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Ascites**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Dyspepsia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Decreased appetite**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hyperuricaemia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypomagnesaemia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Dehydration**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypertriglyceridaemia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Investigations**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Aspartate aminotransferase increased**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Alanine aminotransferase increased**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood thyroid stimulating hormone increased**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood alkaline phosphatase increased**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood creatinine increased**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Dysphonia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Dyspnoea**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Cough**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Epistaxis**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Vascular disorders**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Vascular disorders** and Preferred Term **Hypertension**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders**
 No



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Back pain**
 No



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population

TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Arthralgia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Musculoskeletal chest pain**
 No



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders**
 No



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population

TEAE in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Palmar-plantar erythrodysesthesia syndrome**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Nervous system disorders**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Nervous system disorders** and Preferred Term **Headache**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Nervous system disorders** and Preferred Term **Dysgeusia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Renal and urinary disorders**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Renal and urinary disorders** and Preferred Term **Proteinuria**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Renal and urinary disorders** and Preferred Term **Haematuria**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Infections and infestations**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Infections and infestations** and Preferred Term **Urinary tract infection**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Infections and infestations** and Preferred Term **COVID-19**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Blood and lymphatic system disorders**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Blood and lymphatic system disorders** and Preferred Term **Anaemia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Blood and lymphatic system disorders** and Preferred Term **Thrombocytopenia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Endocrine disorders**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Endocrine disorders** and Preferred Term **Hypothyroidism**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Psychiatric disorders**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE in SOC Term **Psychiatric disorders** and Preferred Term **Insomnia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Asthenia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Fatigue**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Pyrexia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Mucosal inflammation**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 Yes



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Oedema peripheral**
 Yes



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population

TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **General physical health deterioration**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Condition aggravated**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Chills**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Diarrhoea**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Nausea**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Abdominal pain**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Constipation**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Vomiting**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Stomatitis**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Abdominal pain upper**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Proctalgia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Dry mouth**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Ascites**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Dyspepsia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Decreased appetite**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypokalaemia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hyponatraemia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hyperuricaemia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypoalbuminaemia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypomagnesaemia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Dehydration**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hyperglycaemia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypertriglyceridaemia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypophosphataemia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Investigations**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Weight decreased**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Aspartate aminotransferase increased**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Alanine aminotransferase increased**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood bilirubin increased**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood thyroid stimulating hormone increased**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood alkaline phosphatase increased**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Platelet count decreased**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood creatinine increased**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Amylase increased**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Lipase increased**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Dysphonia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Dyspnoea**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Cough**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Epistaxis**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Oropharyngeal pain**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Vascular disorders**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Vascular disorders** and Preferred Term **Hypertension**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Back pain**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Arthralgia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Pain in extremity**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Myalgia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Musculoskeletal chest pain**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Muscle spasms**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Palmar-plantar erythrodysesthesia syndrome**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Rash**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Dry skin**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Nervous system disorders**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Nervous system disorders** and Preferred Term **Headache**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Nervous system disorders** and Preferred Term **Dysgeusia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Nervous system disorders** and Preferred Term **Dizziness**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Renal and urinary disorders**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Renal and urinary disorders** and Preferred Term **Proteinuria**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Renal and urinary disorders** and Preferred Term **Haematuria**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Infections and infestations**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Infections and infestations** and Preferred Term **Urinary tract infection**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Infections and infestations** and Preferred Term **COVID-19**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Infections and infestations** and Preferred Term **Pneumonia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Blood and lymphatic system disorders**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Blood and lymphatic system disorders** and Preferred Term **Anaemia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Blood and lymphatic system disorders** and Preferred Term **Thrombocytopenia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Endocrine disorders**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Endocrine disorders** and Preferred Term **Hypothyroidism**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Psychiatric disorders**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Psychiatric disorders** and Preferred Term **Insomnia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Psychiatric disorders** and Preferred Term **Anxiety**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Psychiatric disorders** and Preferred Term **Confusional state**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Hepatobiliary disorders**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Hepatobiliary disorders** and Preferred Term **Hypertransaminaemia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Hepatobiliary disorders** and Preferred Term **Hyperbilirubinaemia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Asthenia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Fatigue**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Pyrexia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Mucosal inflammation**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 No



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Oedema peripheral**
 No



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population

TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **General physical health deterioration**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Condition aggravated**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Chills**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Diarrhoea**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Nausea**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Abdominal pain**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Constipation**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Vomiting**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Stomatitis**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Abdominal pain upper**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Proctalgia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Dry mouth**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Ascites**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Dyspepsia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Decreased appetite**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypokalaemia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hyponatraemia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hyperuricaemia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypoalbuminaemia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypomagnesaemia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Dehydration**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hyperglycaemia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypertriglyceridaemia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypophosphataemia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Investigations**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Weight decreased**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Aspartate aminotransferase increased**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Alanine aminotransferase increased**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood bilirubin increased**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood thyroid stimulating hormone increased**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood alkaline phosphatase increased**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Platelet count decreased**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood creatinine increased**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Amylase increased**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Lipase increased**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Dysphonia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Dyspnoea**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Cough**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Epistaxis**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Oropharyngeal pain**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Vascular disorders**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Vascular disorders** and Preferred Term **Hypertension**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Back pain**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Arthralgia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Pain in extremity**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Myalgia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Musculoskeletal chest pain**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Muscle spasms**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Palmar-plantar erythrodysesthesia syndrome**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Rash**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Dry skin**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Nervous system disorders**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Nervous system disorders** and Preferred Term **Headache**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Nervous system disorders** and Preferred Term **Dysgeusia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Nervous system disorders** and Preferred Term **Dizziness**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Renal and urinary disorders**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Renal and urinary disorders** and Preferred Term **Proteinuria**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Renal and urinary disorders** and Preferred Term **Haematuria**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Infections and infestations**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Infections and infestations** and Preferred Term **Urinary tract infection**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Infections and infestations** and Preferred Term **COVID-19**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Infections and infestations** and Preferred Term **Pneumonia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Blood and lymphatic system disorders**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Blood and lymphatic system disorders** and Preferred Term **Anaemia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Blood and lymphatic system disorders** and Preferred Term **Thrombocytopenia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Endocrine disorders**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Endocrine disorders** and Preferred Term **Hypothyroidism**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Psychiatric disorders**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Psychiatric disorders** and Preferred Term **Insomnia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Psychiatric disorders** and Preferred Term **Anxiety**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Psychiatric disorders** and Preferred Term **Confusional state**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Hepatobiliary disorders**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE in SOC Term **Hepatobiliary disorders** and Preferred Term **Hypertransaminasaemia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Asthenia**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Fatigue**
 TAS-102



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Pyrexia**
 TAS-102



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population

TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Mucosal inflammation**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 TAS-102



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Oedema peripheral**
 TAS-102



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population

TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **General physical health deterioration**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Condition aggravated**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Chills**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Diarrhoea**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Nausea**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Abdominal pain**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Constipation**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Vomiting**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Stomatitis**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Abdominal pain upper**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Proctalgia**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Dry mouth**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Ascites**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Dyspepsia**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Decreased appetite**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypokalaemia**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hyponatraemia**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hyperuricaemia**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypoalbuminaemia**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypomagnesaemia**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Dehydration**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hyperglycaemia**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypertriglyceridaemia**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypophosphataemia**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Investigations**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Weight decreased**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Aspartate aminotransferase increased**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Alanine aminotransferase increased**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood bilirubin increased**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood thyroid stimulating hormone increased**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood alkaline phosphatase increased**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Platelet count decreased**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood creatinine increased**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Amylase increased**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Lipase increased**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Dysphonia**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Dyspnoea**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Cough**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Epistaxis**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Oropharyngeal pain**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Vascular disorders**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Vascular disorders** and Preferred Term **Hypertension**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Back pain**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Arthralgia**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Pain in extremity**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Myalgia**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Musculoskeletal chest pain**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Muscle spasms**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Palmar-plantar erythrodysesthesia syndrome**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Rash**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Dry skin**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Nervous system disorders**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Nervous system disorders** and Preferred Term **Headache**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Nervous system disorders** and Preferred Term **Dysgeusia**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Nervous system disorders** and Preferred Term **Dizziness**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Renal and urinary disorders**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Renal and urinary disorders** and Preferred Term **Proteinuria**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Renal and urinary disorders** and Preferred Term **Haematuria**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Infections and infestations**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Infections and infestations** and Preferred Term **Urinary tract infection**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Infections and infestations** and Preferred Term **COVID-19**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Infections and infestations** and Preferred Term **Pneumonia**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Blood and lymphatic system disorders**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Blood and lymphatic system disorders** and Preferred Term **Anaemia**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Blood and lymphatic system disorders** and Preferred Term **Thrombocytopenia**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Endocrine disorders**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Endocrine disorders** and Preferred Term **Hypothyroidism**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Psychiatric disorders**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Psychiatric disorders** and Preferred Term **Insomnia**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Psychiatric disorders** and Preferred Term **Anxiety**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Psychiatric disorders** and Preferred Term **Confusional state**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Hepatobiliary disorders**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Hepatobiliary disorders** and Preferred Term **Hypertransaminasaemia**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Hepatobiliary disorders** and Preferred Term **Hyperbilirubinaemia**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions**
 Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Asthenia**
 Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Fatigue**
 Regorafenib



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regora fenib
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Pyrexia**
 Regora fenib



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population

TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Mucosal inflammation**
 Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regora fenib
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 Regora fenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regora fenib
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Oedema peripheral**
 Regora fenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regora fenib
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Condition aggravated**
 Regora fenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regora fenib
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders**
 Regora fenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Diarrhoea**
 Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Nausea**
 Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Abdominal pain**
 Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Constipation**
 Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Vomiting**
 Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Stomatitis**
 Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regora fenib
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Abdominal pain upper**
 Regora fenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Proctalgia**
 Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Dry mouth**
 Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regora fenib
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Ascites**
 Regora fenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Dyspepsia**
 Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regora fenib
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders**
 Regora fenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Decreased appetite**
 Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypokalaemia**
 Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hyponatraemia**
 Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hyperuricaemia**
 Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypoalbuminaemia**
 Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regora fenib
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypomagnesaemia**
 Regora fenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regora fenib
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Dehydration**
 Regora fenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hyperglycaemia**
 Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypertriglyceridaemia**
 Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regora fenib
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypophosphataemia**
 Regora fenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regora fenib
 Safety Population
 TEAE in SOC Term **Investigations**
 Regora fenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Weight decreased**
 Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regora fenib
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Aspartate aminotransferase increased**
 Regora fenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regora fenib
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Alanine aminotransferase increased**
 Regora fenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood bilirubin increased**
 Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regora fenib
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood thyroid stimulating hormone increased**
 Regora fenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regora fenib
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood alkaline phosphatase increased**
 Regora fenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regora fenib
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Platelet count decreased**
 Regora fenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regora fenib
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood creatinine increased**
 Regora fenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders**
 Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Dysphonia**
 Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regora fenib
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Dyspnoea**
 Regora fenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Cough**
 Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Epistaxis**
 Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Vascular disorders**
 Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Vascular disorders** and Preferred Term **Hypertension**
 Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regora fenib
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders**
 Regora fenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regora fenib
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Back pain**
 Regora fenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Arthralgia**
 Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Pain in extremity**
 Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regora fenib
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Myalgia**
 Regora fenib



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regora fenib
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders**
 Regora fenib



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population

TEAE in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Palmar-plantar erythrodysesthesia syndrome**
 Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Rash**
 Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regora fenib
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Dry skin**
 Regora fenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regora fenib
 Safety Population
 TEAE in SOC Term **Nervous system disorders**
 Regora fenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Nervous system disorders** and Preferred Term **Headache**
 Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Nervous system disorders** and Preferred Term **Dysgeusia**
 Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Nervous system disorders** and Preferred Term **Dizziness**
 Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Renal and urinary disorders**
 Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Renal and urinary disorders** and Preferred Term **Proteinuria**
 Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regora fenib
 Safety Population
 TEAE in SOC Term **Renal and urinary disorders** and Preferred Term **Haematuria**
 Regora fenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regora fenib
 Safety Population
 TEAE in SOC Term **Infections and infestations**
 Regora fenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regora fenib
 Safety Population
 TEAE in SOC Term **Infections and infestations** and Preferred Term **Urinary tract infection**
 Regora fenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Infections and infestations** and Preferred Term **COVID-19**
 Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Infections and infestations** and Preferred Term **Pneumonia**
 Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regora fenib
 Safety Population
 TEAE in SOC Term **Blood and lymphatic system disorders**
 Regora fenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regora fenib
 Safety Population
 TEAE in SOC Term **Blood and lymphatic system disorders** and Preferred Term **Anaemia**
 Regora fenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Blood and lymphatic system disorders** and Preferred Term **Thrombocytopenia**
 Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Endocrine disorders**
 Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Endocrine disorders** and Preferred Term **Hypothyroidism**
 Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regora fenib
 Safety Population
 TEAE in SOC Term **Psychiatric disorders**
 Regora fenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regora fenib
 Safety Population
 TEAE in SOC Term **Psychiatric disorders** and Preferred Term **Insomnia**
 Regora fenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Psychiatric disorders** and Preferred Term **Anxiety**
 Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Psychiatric disorders** and Preferred Term **Confusional state**
 Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regora fenib
 Safety Population
 TEAE in SOC Term **Hepatobiliary disorders**
 Regora fenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regora fenib
 Safety Population
 TEAE in SOC Term **Hepatobiliary disorders** and Preferred Term **Hypertransaminasaemia**
 Regora fenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regora fenib
 Safety Population
 TEAE in SOC Term **Hepatobiliary disorders** and Preferred Term **Hyperbilirubinaemia**
 Regora fenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Asthenia**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Fatigue**
 TAS-102 and Regorafenib



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Pyrexia**
 TAS-102 and Regorafenib



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population

TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Mucosal inflammation**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 TAS-102 and Regorafenib



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Oedema peripheral**
 TAS-102 and Regorafenib



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population

TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **General physical health deterioration**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Condition aggravated**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Chills**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Diarrhoea**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Nausea**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Abdominal pain**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Constipation**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Vomiting**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Stomatitis**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Abdominal pain upper**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Proctalgia**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Dry mouth**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Ascites**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Dyspepsia**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Decreased appetite**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypokalaemia**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hyponatraemia**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hyperuricaemia**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypoalbuminaemia**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypomagnesaemia**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Dehydration**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hyperglycaemia**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypertriglyceridaemia**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypophosphataemia**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Investigations**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Weight decreased**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Aspartate aminotransferase increased**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Alanine aminotransferase increased**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood bilirubin increased**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood thyroid stimulating hormone increased**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood alkaline phosphatase increased**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Platelet count decreased**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood creatinine increased**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Amylase increased**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Lipase increased**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Dysphonia**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Dyspnoea**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Cough**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Epistaxis**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Oropharyngeal pain**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Vascular disorders**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Vascular disorders** and Preferred Term **Hypertension**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Back pain**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Arthralgia**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Pain in extremity**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Myalgia**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Musculoskeletal chest pain**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Muscle spasms**
 TAS-102 and Regorafenib



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders**
 TAS-102 and Regorafenib



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population

TEAE in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Palmar-plantar erythrodysesthesia syndrome**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Rash**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Dry skin**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Nervous system disorders**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Nervous system disorders** and Preferred Term **Headache**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Nervous system disorders** and Preferred Term **Dysgeusia**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Nervous system disorders** and Preferred Term **Dizziness**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Renal and urinary disorders**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Renal and urinary disorders** and Preferred Term **Proteinuria**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Renal and urinary disorders** and Preferred Term **Haematuria**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Infections and infestations**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Infections and infestations** and Preferred Term **Urinary tract infection**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Infections and infestations** and Preferred Term **COVID-19**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Infections and infestations** and Preferred Term **Pneumonia**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Blood and lymphatic system disorders**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Blood and lymphatic system disorders** and Preferred Term **Anaemia**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Blood and lymphatic system disorders** and Preferred Term **Thrombocytopenia**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Endocrine disorders**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Endocrine disorders** and Preferred Term **Hypothyroidism**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Psychiatric disorders**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Psychiatric disorders** and Preferred Term **Insomnia**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Psychiatric disorders** and Preferred Term **Anxiety**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Psychiatric disorders** and Preferred Term **Confusional state**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Hepatobiliary disorders**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE in SOC Term **Hepatobiliary disorders** and Preferred Term **Hypertransaminasaemia**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Asthenia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Fatigue**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Pyrexia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Mucosal inflammation**
 Yes



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 Yes



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population


TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Oedema peripheral**
 Yes



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population


TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **General physical health deterioration**
 Yes



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population

TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Condition aggravated**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Chills**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Diarrhoea**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Nausea**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Abdominal pain**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Constipation**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Vomiting**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Stomatitis**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Abdominal pain upper**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Proctalgia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Dry mouth**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Ascites**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Dyspepsia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Decreased appetite**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypokalaemia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hyponatraemia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hyperuricaemia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypoalbuminaemia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypomagnesaemia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Dehydration**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hyperglycaemia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypertriglyceridaemia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypophosphataemia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Investigations**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Weight decreased**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Aspartate aminotransferase increased**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Alanine aminotransferase increased**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood bilirubin increased**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood thyroid stimulating hormone increased**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood alkaline phosphatase increased**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Platelet count decreased**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood creatinine increased**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Amylase increased**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Lipase increased**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Dysphonia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Dyspnoea**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Cough**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Epistaxis**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Oropharyngeal pain**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Vascular disorders**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Vascular disorders** and Preferred Term **Hypertension**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Back pain**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Arthralgia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Pain in extremity**
 Yes



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Myalgia**
 Yes



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population

TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Musculoskeletal chest pain**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Muscle spasms**
 Yes



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders**
 Yes



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population

TEAE in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Palmar-plantar erythrodysesthesia syndrome**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Rash**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Dry skin**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Nervous system disorders**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Nervous system disorders** and Preferred Term **Headache**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Nervous system disorders** and Preferred Term **Dysgeusia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Nervous system disorders** and Preferred Term **Dizziness**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Renal and urinary disorders**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Renal and urinary disorders** and Preferred Term **Proteinuria**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Renal and urinary disorders** and Preferred Term **Haematuria**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Infections and infestations**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Infections and infestations** and Preferred Term **Urinary tract infection**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Infections and infestations** and Preferred Term **COVID-19**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Infections and infestations** and Preferred Term **Pneumonia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Blood and lymphatic system disorders**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Blood and lymphatic system disorders** and Preferred Term **Anaemia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Blood and lymphatic system disorders** and Preferred Term **Thrombocytopenia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Endocrine disorders**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Endocrine disorders** and Preferred Term **Hypothyroidism**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Psychiatric disorders**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Psychiatric disorders** and Preferred Term **Insomnia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Psychiatric disorders** and Preferred Term **Anxiety**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Psychiatric disorders** and Preferred Term **Confusional state**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Hepatobiliary disorders**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Hepatobiliary disorders** and Preferred Term **Hypertransaminasaemia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Hepatobiliary disorders** and Preferred Term **Hyperbilirubinaemia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Asthenia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Fatigue**
 No



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Pyrexia**
 No



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population


TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Mucosal inflammation**
 No



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population

TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 No



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Oedema peripheral**
 No



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population


TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **General physical health deterioration**
 No



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population

TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Condition aggravated**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Chills**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Diarrhoea**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Nausea**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Abdominal pain**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Constipation**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Vomiting**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Stomatitis**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Abdominal pain upper**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Proctalgia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Dry mouth**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Dyspepsia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Decreased appetite**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypokalaemia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hyponatraemia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hyperuricaemia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypoalbuminaemia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypomagnesaemia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Dehydration**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hyperglycaemia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypertriglyceridaemia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypophosphataemia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Investigations**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Weight decreased**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Aspartate aminotransferase increased**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Alanine aminotransferase increased**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood bilirubin increased**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood thyroid stimulating hormone increased**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood alkaline phosphatase increased**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Platelet count decreased**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood creatinine increased**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Amylase increased**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Lipase increased**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Dysphonia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Dyspnoea**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Cough**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Epistaxis**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Oropharyngeal pain**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Vascular disorders**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Vascular disorders** and Preferred Term **Hypertension**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Back pain**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Arthralgia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Pain in extremity**
 No



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Myalgia**
 No



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population

TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Musculoskeletal chest pain**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Muscle spasms**
 No



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders**
 No



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population

TEAE in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Palmar-plantar erythrodysesthesia syndrome**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Rash**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Dry skin**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Nervous system disorders**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Nervous system disorders** and Preferred Term **Headache**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Nervous system disorders** and Preferred Term **Dysgeusia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Nervous system disorders** and Preferred Term **Dizziness**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Renal and urinary disorders**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Renal and urinary disorders** and Preferred Term **Proteinuria**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Renal and urinary disorders** and Preferred Term **Haematuria**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Infections and infestations**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Infections and infestations** and Preferred Term **Urinary tract infection**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Infections and infestations** and Preferred Term **COVID-19**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Infections and infestations** and Preferred Term **Pneumonia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Blood and lymphatic system disorders**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Blood and lymphatic system disorders** and Preferred Term **Anaemia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Blood and lymphatic system disorders** and Preferred Term **Thrombocytopenia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Endocrine disorders**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Endocrine disorders** and Preferred Term **Hypothyroidism**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Psychiatric disorders**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Psychiatric disorders** and Preferred Term **Insomnia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Psychiatric disorders** and Preferred Term **Anxiety**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.30
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Psychiatric disorders** and Preferred Term **Confusional state**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Hepatobiliary disorders**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE in SOC Term **Hepatobiliary disorders** and Preferred Term **Hypertransaminasaemia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Asthenia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Fatigue**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Pyrexia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Mucosal inflammation**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Oedema peripheral**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **General physical health deterioration**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Chills**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Diarrhoea**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Nausea**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Abdominal pain**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Constipation**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Vomiting**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Stomatitis**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Abdominal pain upper**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Proctalgia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Ascites**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Dyspepsia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Decreased appetite**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypokalaemia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hyponatraemia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypomagnesaemia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Dehydration**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypophosphataemia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Investigations**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Weight decreased**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Aspartate aminotransferase increased**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Alanine aminotransferase increased**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood bilirubin increased**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood thyroid stimulating hormone increased**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood alkaline phosphatase increased**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Platelet count decreased**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood creatinine increased**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Amylase increased**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Lipase increased**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Dysphonia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Dyspnoea**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Cough**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Epistaxis**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Oropharyngeal pain**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Vascular disorders**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Vascular disorders** and Preferred Term **Hypertension**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Back pain**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Arthralgia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Pain in extremity**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Musculoskeletal chest pain**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Muscle spasms**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Palmar-plantar erythrodysesthesia syndrome**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Rash**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Dry skin**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Nervous system disorders**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Nervous system disorders** and Preferred Term **Headache**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Renal and urinary disorders**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Renal and urinary disorders** and Preferred Term **Proteinuria**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Infections and infestations**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Infections and infestations** and Preferred Term **COVID-19**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Infections and infestations** and Preferred Term **Pneumonia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Blood and lymphatic system disorders**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Blood and lymphatic system disorders** and Preferred Term **Anaemia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Blood and lymphatic system disorders** and Preferred Term **Thrombocytopenia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Endocrine disorders**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Endocrine disorders** and Preferred Term **Hypothyroidism**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Psychiatric disorders**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Psychiatric disorders** and Preferred Term **Insomnia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Psychiatric disorders** and Preferred Term **Confusional state**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Hepatobiliary disorders**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Hepatobiliary disorders** and Preferred Term **Hypertransaminasaemia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Asthenia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Fatigue**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Pyrexia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Mucosal inflammation**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Oedema peripheral**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **General physical health deterioration**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Condition aggravated**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Chills**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Diarrhoea**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Nausea**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Abdominal pain**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Constipation**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Vomiting**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Stomatitis**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Abdominal pain upper**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Proctalgia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Dry mouth**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Ascites**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Dyspepsia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Decreased appetite**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypokalaemia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hyponatraemia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hyperuricaemia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypoalbuminaemia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypomagnesaemia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Dehydration**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hyperglycaemia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypertriglyceridaemia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypophosphataemia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Investigations**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Weight decreased**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Aspartate aminotransferase increased**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Alanine aminotransferase increased**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood bilirubin increased**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood thyroid stimulating hormone increased**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood alkaline phosphatase increased**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Platelet count decreased**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood creatinine increased**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Amylase increased**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Lipase increased**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Dysphonia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Dyspnoea**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Cough**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Epistaxis**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Oropharyngeal pain**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Vascular disorders**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Vascular disorders** and Preferred Term **Hypertension**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Back pain**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Arthralgia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Pain in extremity**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Myalgia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Musculoskeletal chest pain**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Muscle spasms**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Palmar-plantar erythrodysesthesia syndrome**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Rash**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Dry skin**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Nervous system disorders**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Nervous system disorders** and Preferred Term **Headache**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Nervous system disorders** and Preferred Term **Dysgeusia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Nervous system disorders** and Preferred Term **Dizziness**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Renal and urinary disorders**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Renal and urinary disorders** and Preferred Term **Proteinuria**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Renal and urinary disorders** and Preferred Term **Haematuria**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Infections and infestations**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Infections and infestations** and Preferred Term **Urinary tract infection**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Infections and infestations** and Preferred Term **COVID-19**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Infections and infestations** and Preferred Term **Pneumonia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Blood and lymphatic system disorders**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Blood and lymphatic system disorders** and Preferred Term **Anaemia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Blood and lymphatic system disorders** and Preferred Term **Thrombocytopenia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Endocrine disorders**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Endocrine disorders** and Preferred Term **Hypothyroidism**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Psychiatric disorders**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Psychiatric disorders** and Preferred Term **Insomnia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Psychiatric disorders** and Preferred Term **Anxiety**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Psychiatric disorders** and Preferred Term **Confusional state**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Hepatobiliary disorders**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE in SOC Term **Hepatobiliary disorders** and Preferred Term **Hypertransaminasaemia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Asthenia**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Fatigue**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Pyrexia**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Mucosal inflammation**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Oedema peripheral**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **General physical health deterioration**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Condition aggravated**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Chills**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Diarrhoea**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Nausea**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Abdominal pain**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Constipation**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Vomiting**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Stomatitis**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Abdominal pain upper**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Proctalgia**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Dry mouth**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Ascites**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Dyspepsia**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Decreased appetite**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypokalaemia**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hyponatraemia**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hyperuricaemia**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypoalbuminaemia**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypomagnesaemia**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Dehydration**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hyperglycaemia**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypertriglyceridaemia**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypophosphataemia**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Investigations**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Weight decreased**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Aspartate aminotransferase increased**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Alanine aminotransferase increased**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood bilirubin increased**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood thyroid stimulating hormone increased**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood alkaline phosphatase increased**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Platelet count decreased**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood creatinine increased**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Amylase increased**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Dysphonia**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Dyspnoea**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Cough**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Epistaxis**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Oropharyngeal pain**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Vascular disorders**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Vascular disorders** and Preferred Term **Hypertension**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Back pain**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Arthralgia**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Pain in extremity**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Myalgia**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Musculoskeletal chest pain**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Muscle spasms**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Palmar-plantar erythrodysesthesia syndrome**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Rash**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Dry skin**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Nervous system disorders**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Nervous system disorders** and Preferred Term **Headache**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Nervous system disorders** and Preferred Term **Dysgeusia**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Nervous system disorders** and Preferred Term **Dizziness**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Renal and urinary disorders**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Renal and urinary disorders** and Preferred Term **Proteinuria**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Infections and infestations**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Infections and infestations** and Preferred Term **Urinary tract infection**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Infections and infestations** and Preferred Term **COVID-19**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Infections and infestations** and Preferred Term **Pneumonia**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Blood and lymphatic system disorders**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Blood and lymphatic system disorders** and Preferred Term **Anaemia**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Blood and lymphatic system disorders** and Preferred Term **Thrombocytopenia**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Endocrine disorders**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Endocrine disorders** and Preferred Term **Hypothyroidism**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Psychiatric disorders**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Psychiatric disorders** and Preferred Term **Insomnia**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Psychiatric disorders** and Preferred Term **Anxiety**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Hepatobiliary disorders**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Hepatobiliary disorders** and Preferred Term **Hypertransaminasaemia**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Hepatobiliary disorders** and Preferred Term **Hyperbilirubinaemia**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Asthenia**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Fatigue**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Pyrexia**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Mucosal inflammation**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Oedema peripheral Multiple**




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **General physical health deterioration**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Condition aggravated**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Chills**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Diarrhoea**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Nausea**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Abdominal pain**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Constipation**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Vomiting**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Stomatitis**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Abdominal pain upper**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Proctalgia**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Dry mouth**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Ascites**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Dyspepsia**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Decreased appetite**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypokalaemia**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hyponatraemia**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hyperuricaemia**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypoalbuminaemia**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypomagnesaemia**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Dehydration**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hyperglycaemia**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypertriglyceridaemia**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypophosphataemia**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Investigations**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Weight decreased**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Aspartate aminotransferase increased**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Alanine aminotransferase increased**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood bilirubin increased**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood thyroid stimulating hormone increased Multiple**




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood alkaline phosphatase increased**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Platelet count decreased**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood creatinine increased**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Amylase increased**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Lipase increased**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Dysphonia**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Dyspnoea**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Cough**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Epistaxis**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Oropharyngeal pain**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Vascular disorders**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Vascular disorders** and Preferred Term **Hypertension**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Back pain**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Arthralgia**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Pain in extremity**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Myalgia**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Musculoskeletal chest pain**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Muscle spasms**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Palmar-plantar erythrodysesthesia syndrome**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Rash**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Dry skin**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Nervous system disorders**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Nervous system disorders** and Preferred Term **Headache**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Nervous system disorders** and Preferred Term **Dysgeusia**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Nervous system disorders** and Preferred Term **Dizziness**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Renal and urinary disorders**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Renal and urinary disorders** and Preferred Term **Proteinuria**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Renal and urinary disorders** and Preferred Term **Haematuria**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Infections and infestations**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Infections and infestations** and Preferred Term **Urinary tract infection**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Infections and infestations** and Preferred Term **COVID-19**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Infections and infestations** and Preferred Term **Pneumonia**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Blood and lymphatic system disorders**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Blood and lymphatic system disorders** and Preferred Term **Anaemia**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Blood and lymphatic system disorders** and Preferred Term **Thrombocytopenia**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Endocrine disorders**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Endocrine disorders** and Preferred Term **Hypothyroidism**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Psychiatric disorders**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Psychiatric disorders** and Preferred Term **Insomnia**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Psychiatric disorders** and Preferred Term **Anxiety**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Psychiatric disorders** and Preferred Term **Confusional state**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Hepatobiliary disorders**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE in SOC Term **Hepatobiliary disorders** and Preferred Term **Hypertransaminasaemia**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Asthenia**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Fatigue**
 Single



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Pyrexia**
 Single



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population


TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Mucosal inflammation**
 Single



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population

TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 Single



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Oedema peripheral**
 Single



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population


TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **General physical health deterioration**
 Single



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population

TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Condition aggravated**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Chills**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Diarrhoea**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Nausea**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Abdominal pain**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Constipation**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Vomiting**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Stomatitis**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Abdominal pain upper**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Proctalgia**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Dry mouth**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Ascites**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Dyspepsia**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Decreased appetite**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypokalaemia**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hyponatraemia**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hyperuricaemia**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypoalbuminaemia**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypomagnesaemia**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Dehydration**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hyperglycaemia**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypertriglyceridaemia**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypophosphataemia**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Investigations**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Weight decreased**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Aspartate aminotransferase increased**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Alanine aminotransferase increased**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood bilirubin increased**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood thyroid stimulating hormone increased**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood alkaline phosphatase increased**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Platelet count decreased**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood creatinine increased**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Amylase increased**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Dysphonia**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Dyspnoea**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Cough**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Epistaxis**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Oropharyngeal pain**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Vascular disorders**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Vascular disorders** and Preferred Term **Hypertension**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Back pain**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Arthralgia**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Pain in extremity**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Myalgia**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Musculoskeletal chest pain**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Muscle spasms**
 Single



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders**
 Single



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population

TEAE in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Palmar-plantar erythrodysesthesia syndrome**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Rash**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Dry skin**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Nervous system disorders**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Nervous system disorders** and Preferred Term **Headache**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Nervous system disorders** and Preferred Term **Dysgeusia**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Nervous system disorders** and Preferred Term **Dizziness**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Renal and urinary disorders**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Renal and urinary disorders** and Preferred Term **Proteinuria**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Infections and infestations**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Infections and infestations** and Preferred Term **Urinary tract infection**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Infections and infestations** and Preferred Term **COVID-19**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Infections and infestations** and Preferred Term **Pneumonia**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Blood and lymphatic system disorders**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Blood and lymphatic system disorders** and Preferred Term **Anaemia**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Blood and lymphatic system disorders** and Preferred Term **Thrombocytopenia**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Endocrine disorders**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Endocrine disorders** and Preferred Term **Hypothyroidism**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Psychiatric disorders**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Psychiatric disorders** and Preferred Term **Insomnia**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Psychiatric disorders** and Preferred Term **Anxiety**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Hepatobiliary disorders**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Hepatobiliary disorders** and Preferred Term **Hypertransaminasaemia**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Hepatobiliary disorders** and Preferred Term **Hyperbilirubinaemia**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Asthenia**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Fatigue**
 Multiple



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Pyrexia**
 Multiple



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population

TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Mucosal inflammation**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 Multiple



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Oedema peripheral Multiple**



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population


TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **General physical health deterioration**
 Multiple



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population

TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Condition aggravated**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Chills**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Diarrhoea**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Nausea**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Abdominal pain**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Constipation**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Vomiting**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Stomatitis**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Abdominal pain upper**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Proctalgia**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Dry mouth**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Ascites**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Dyspepsia**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Decreased appetite**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypokalaemia**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hyponatraemia**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hyperuricaemia**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypoalbuminaemia**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypomagnesaemia**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Dehydration**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hyperglycaemia**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypertriglyceridaemia**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypophosphataemia**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Investigations**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Weight decreased**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Aspartate aminotransferase increased**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Alanine aminotransferase increased**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood bilirubin increased**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood thyroid stimulating hormone increased Multiple**




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood alkaline phosphatase increased**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Platelet count decreased**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood creatinine increased**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Amylase increased**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Lipase increased**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Dysphonia**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Dyspnoea**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Cough**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Epistaxis**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Oropharyngeal pain**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Vascular disorders**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Vascular disorders** and Preferred Term **Hypertension**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Back pain**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Arthralgia**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Pain in extremity**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Myalgia**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Musculoskeletal chest pain**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Muscle spasms**
 Multiple



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders**
 Multiple



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population

TEAE in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Palmar-plantar erythrodysesthesia syndrome**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Rash**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Dry skin**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Nervous system disorders**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Nervous system disorders** and Preferred Term **Headache**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Nervous system disorders** and Preferred Term **Dysgeusia**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Nervous system disorders** and Preferred Term **Dizziness**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Renal and urinary disorders**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Renal and urinary disorders** and Preferred Term **Proteinuria**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Renal and urinary disorders** and Preferred Term **Haematuria**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Infections and infestations**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Infections and infestations** and Preferred Term **Urinary tract infection**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Infections and infestations** and Preferred Term **COVID-19**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Infections and infestations** and Preferred Term **Pneumonia**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Blood and lymphatic system disorders**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Blood and lymphatic system disorders** and Preferred Term **Anaemia**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Blood and lymphatic system disorders** and Preferred Term **Thrombocytopenia**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Endocrine disorders**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Endocrine disorders** and Preferred Term **Hypothyroidism**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Psychiatric disorders**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Psychiatric disorders** and Preferred Term **Insomnia**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Psychiatric disorders** and Preferred Term **Anxiety**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Psychiatric disorders** and Preferred Term **Confusional state**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Hepatobiliary disorders**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE in SOC Term **Hepatobiliary disorders** and Preferred Term **Hypertransaminasaemia**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Asthenia**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Fatigue**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Pyrexia**
 < 18.5



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Mucosal inflammation**
 < 18.5



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population

TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 < 18.5



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Oedema peripheral**
 < 18.5



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population

TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **General physical health deterioration**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Condition aggravated**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Chills**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Diarrhoea**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Nausea**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Abdominal pain**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Constipation**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Vomiting**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Stomatitis**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Abdominal pain upper**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Dry mouth**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Ascites**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Decreased appetite**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypokalaemia**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hyponatraemia**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hyperuricaemia**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypoalbuminaemia**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Dehydration**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Investigations**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Weight decreased**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Aspartate aminotransferase increased**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Alanine aminotransferase increased**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood bilirubin increased**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood alkaline phosphatase increased**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Platelet count decreased**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood creatinine increased**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Dysphonia**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Dyspnoea**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Cough**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Epistaxis**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Oropharyngeal pain**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Vascular disorders**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Vascular disorders** and Preferred Term **Hypertension**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Back pain**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Pain in extremity**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Myalgia**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Muscle spasms**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Palmar-plantar erythrodysesthesia syndrome**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Rash**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Dry skin**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Nervous system disorders**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Nervous system disorders** and Preferred Term **Headache**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Nervous system disorders** and Preferred Term **Dysgeusia**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Nervous system disorders** and Preferred Term **Dizziness**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Renal and urinary disorders**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Renal and urinary disorders** and Preferred Term **Proteinuria**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Renal and urinary disorders** and Preferred Term **Haematuria**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Infections and infestations**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Infections and infestations** and Preferred Term **Pneumonia**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Blood and lymphatic system disorders**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Blood and lymphatic system disorders** and Preferred Term **Anaemia**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Blood and lymphatic system disorders** and Preferred Term **Thrombocytopenia**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Endocrine disorders**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Endocrine disorders** and Preferred Term **Hypothyroidism**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Psychiatric disorders**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Psychiatric disorders** and Preferred Term **Insomnia**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Psychiatric disorders** and Preferred Term **Confusional state**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Hepatobiliary disorders**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Hepatobiliary disorders** and Preferred Term **Hypertransaminasaemia**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Asthenia**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Fatigue**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Pyrexia**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Mucosal inflammation**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 ≥ 18.5 to < 24



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Oedema peripheral**
 ≥ 18.5 to < 24



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population

TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **General physical health deterioration**
 >= 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Condition aggravated**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Chills**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Diarrhoea**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Nausea**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Abdominal pain**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Constipation**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Vomiting**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Stomatitis**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Abdominal pain upper**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Proctalgia**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Dry mouth**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Ascites**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Dyspepsia**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Decreased appetite**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypokalaemia**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hyponatraemia**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hyperuricaemia**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypoalbuminaemia**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypomagnesaemia**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Dehydration**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hyperglycaemia**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypertriglyceridaemia**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypophosphataemia**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Investigations**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Weight decreased**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Aspartate aminotransferase increased**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Alanine aminotransferase increased**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood bilirubin increased**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood thyroid stimulating hormone increased**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood alkaline phosphatase increased**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Platelet count decreased**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood creatinine increased**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Amylase increased**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Lipase increased**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Dysphonia**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Dyspnoea**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Cough**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Epistaxis**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Oropharyngeal pain**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Vascular disorders**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Vascular disorders** and Preferred Term **Hypertension**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Back pain**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Arthralgia**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Pain in extremity**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Myalgia**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Musculoskeletal chest pain**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Muscle spasms**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Palmar-plantar erythrodysesthesia syndrome**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Rash**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Dry skin**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Nervous system disorders**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Nervous system disorders** and Preferred Term **Headache**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Nervous system disorders** and Preferred Term **Dysgeusia**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Nervous system disorders** and Preferred Term **Dizziness**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Renal and urinary disorders**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Renal and urinary disorders** and Preferred Term **Proteinuria**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Renal and urinary disorders** and Preferred Term **Haematuria**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Infections and infestations**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Infections and infestations** and Preferred Term **Urinary tract infection**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Infections and infestations** and Preferred Term **COVID-19**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Infections and infestations** and Preferred Term **Pneumonia**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Blood and lymphatic system disorders**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Blood and lymphatic system disorders** and Preferred Term **Anaemia**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Blood and lymphatic system disorders** and Preferred Term **Thrombocytopenia**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Endocrine disorders**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Endocrine disorders** and Preferred Term **Hypothyroidism**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Psychiatric disorders**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Psychiatric disorders** and Preferred Term **Insomnia**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Psychiatric disorders** and Preferred Term **Anxiety**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Psychiatric disorders** and Preferred Term **Confusional state**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Hepatobiliary disorders**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Hepatobiliary disorders** and Preferred Term **Hypertransaminasaemia**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Hepatobiliary disorders** and Preferred Term **Hyperbilirubinaemia**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions**
 >= 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Asthenia**
 >= 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Fatigue**
 >= 24



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Pyrexia**
 >= 24



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population


TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Mucosal inflammation**
 >= 24



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population

TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 >= 24



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Oedema peripheral**
 >= 24



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population

TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **General physical health deterioration**
 >= 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Condition aggravated**
 ≥ 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Chills**
 >= 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders**
 ≥ 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Diarrhoea**
 ≥ 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Nausea**
 ≥ 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Abdominal pain**
 ≥ 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Constipation**
 >= 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Vomiting**
 ≥ 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Stomatitis**
 ≥ 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Abdominal pain upper**
 ≥ 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Proctalgia**
 >= 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Dry mouth**
 ≥ 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Ascites**
 ≥ 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Gastrointestinal disorders** and Preferred Term **Dyspepsia**
 ≥ 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders**
 >= 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Decreased appetite**
 >= 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypokalaemia**
 ≥ 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hyponatraemia**
 >= 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hyperuricaemia**
 >= 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypoalbuminaemia**
 ≥ 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypomagnesaemia**
 >= 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Dehydration**
 ≥ 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hyperglycaemia**
 >= 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypertriglyceridaemia**
 ≥ 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Metabolism and nutrition disorders** and Preferred Term **Hypophosphataemia**
 >= 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Investigations**
 ≥ 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Weight decreased**
 ≥ 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Aspartate aminotransferase increased**
 >= 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Alanine aminotransferase increased**
 ≥ 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood bilirubin increased**
 ≥ 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood thyroid stimulating hormone increased**
 >= 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood alkaline phosphatase increased**
 ≥ 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Platelet count decreased**
 ≥ 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Blood creatinine increased**
 >= 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Amylase increased**
 ≥ 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Investigations** and Preferred Term **Lipase increased**
 ≥ 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders**
 >= 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Dysphonia**
 >= 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Dyspnoea**
 >= 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Cough**
 >= 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Epistaxis**
 >= 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Respiratory, thoracic and mediastinal disorders** and Preferred Term **Oropharyngeal pain**
 >= 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Vascular disorders**
 ≥ 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Vascular disorders** and Preferred Term **Hypertension**
 ≥ 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders**
 >= 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Back pain**
 >= 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Arthralgia**
 >= 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Pain in extremity**
 >= 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Myalgia**
 >= 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Musculoskeletal chest pain**
 ≥ 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Musculoskeletal and connective tissue disorders** and Preferred Term **Muscle spasms**
 >= 24



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders**
 >= 24



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population

TEAE in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Palmar-plantar erythrodysesthesia syndrome**
 >= 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Rash**
 >= 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Dry skin**
 >= 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Nervous system disorders**
 ≥ 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Nervous system disorders** and Preferred Term **Headache**
 ≥ 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Nervous system disorders** and Preferred Term **Dysgeusia**
 ≥ 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Nervous system disorders** and Preferred Term **Dizziness**
 >= 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Renal and urinary disorders**
 ≥ 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Renal and urinary disorders** and Preferred Term **Proteinuria**
 ≥ 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Renal and urinary disorders** and Preferred Term **Haematuria**
 >= 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Infections and infestations**
 >= 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Infections and infestations** and Preferred Term **Urinary tract infection**
 >= 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Infections and infestations** and Preferred Term **COVID-19**
 >= 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Infections and infestations** and Preferred Term **Pneumonia**
 ≥ 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Blood and lymphatic system disorders**
 ≥ 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Blood and lymphatic system disorders** and Preferred Term **Anaemia**
 ≥ 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Blood and lymphatic system disorders** and Preferred Term **Thrombocytopenia**
 ≥ 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Endocrine disorders**
 ≥ 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Endocrine disorders** and Preferred Term **Hypothyroidism**
 ≥ 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Psychiatric disorders**
 ≥ 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Psychiatric disorders** and Preferred Term **Insomnia**
 ≥ 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Psychiatric disorders** and Preferred Term **Anxiety**
 ≥ 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Psychiatric disorders** and Preferred Term **Confusional state**
 >= 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Hepatobiliary disorders**
 ≥ 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.1.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE in SOC Term **Hepatobiliary disorders** and Preferred Term **Hypertransaminasaemia**
 ≥ 24



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.3.3B
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Age
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions**
 <65 years



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.3.3B
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Age
 Safety Population

Serious TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 <65 years



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.3.3B
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Age
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions**
 >=65 years



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.3.3B
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Age
 Safety Population

Serious TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 >=65 years



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.3.3C
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Sex
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions**
 Male



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.3.3C
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Sex
 Safety Population

Serious TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 Male




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.3.3C
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Sex
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions**
 Female




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.3.3D
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Geographic Region
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions**
 North America




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.3.3D
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Geographic Region
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions**
 North America




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.3.3D
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Geographic Region
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 North America




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.3.3D
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Geographic Region
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions**
 Europe




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.3.3D
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Geographic Region
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 Europe




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.3.3D
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Geographic Region
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions**
 Asia




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.3.3E
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by ECOG PS
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions**
 ECOG: 0



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.3.3E
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by ECOG PS
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions**
 ECOG: 0



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.3.3E
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by ECOG PS
 Safety Population

Serious TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 ECOG: 0




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.3.3E
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by ECOG PS
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions**
 ECOG: 1




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.3.3F
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Duration of Metastatic Disease
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions**
 ≤ 18 months



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.3.3F
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Duration of Metastatic Disease
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions**
 ≤ 18 months



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.3.3F
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Duration of Metastatic Disease
 Safety Population

Serious TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 ≤ 18 months




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.3.3F
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Duration of Metastatic Disease
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions**
 > 18 months




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.3.3G
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Primary Tumor Site at 1st Diagnosis
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions**
 Colon



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.3.3G
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Primary Tumor Site at 1st Diagnosis
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions**
 Colon



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.3.3G
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Primary Tumor Site at 1st Diagnosis
 Safety Population

Serious TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 Colon



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.3.3G
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Primary Tumor Site at 1st Diagnosis
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions**
 Rectum



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.3.3G
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Primary Tumor Site at 1st Diagnosis
 Safety Population

Serious TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 Rectum




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.3.3G
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Primary Tumor Site at 1st Diagnosis
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions**
 Colon and Rectum




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.3.3H
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by RAS Status
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions**
 WT (Wild Type)




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.3.3H
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by RAS Status
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions**
 WT (Wild Type)




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.3.3H
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by RAS Status
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 WT (Wild Type)




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.3.3H
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by RAS Status
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions**
 Mutant




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.3.3I
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by BRAF Status
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions**
 WT (Wild Type)




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.3.3I
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by BRAF Status
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions**
 WT (Wild Type)




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.3.3I
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by BRAF Status
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 WT (Wild Type)




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.3.3I
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by BRAF Status
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions**
 V600 E Mutation




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.3.3I
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by BRAF Status
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 V600 E Mutation




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.3.3I
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by BRAF Status
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions**
 Other




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.3.3J
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions**
 <=3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.3.3J
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions**
 <=3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.3.3J
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 <=3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.3.3J
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.3.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions**
 ≤3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.3.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions**
 <=3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.3.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 <=3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.3.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.3.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions**
 Yes



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.3.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions**
 Yes



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.3.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population

Serious TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.3.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.3.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions**
 Yes



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.3.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions**
 Yes



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.3.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population

Serious TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.3.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.3.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions**
 TAS-102



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.3.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions**
 TAS-102



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.3.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population

Serious TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 TAS-102



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.3.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions**
 Regorafenib



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.3.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population

Serious TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.3.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.3.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions**
 Yes



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.3.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions**
 Yes



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.3.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population

Serious TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.3.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.3.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.3.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.3.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.3.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.3.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.3.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.3.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.3.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.3.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions**
 Single



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.3.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions**
 Single



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.3.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population

Serious TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.3.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.3.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.3.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.3.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.3.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.3.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.3.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 Serious TEAE in SOC Term **General disorders and administration site conditions**
 ≥ 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3B
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Age
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions**
 <65 years



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3B
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Age
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions**
 <65 years



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3B
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Age
 Safety Population


TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 <65 years



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3B
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Age
 Safety Population

TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Asthenia**
 <65 years




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3B
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Age
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders**
 <65 years




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3B
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Age
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders** and Preferred Term **Hypertension**
 <65 years



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3B
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Age
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Skin and subcutaneous tissue disorders**
 <65 years



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3B
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Age
 Safety Population

TEAE \geq CTCAE Grade 3 in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Palmar-plantar erythrodysesthesia syndrome**
 <65 years



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3B
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Age
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions**
 ≥65 years



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3B
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Age
 Safety Population


TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 ≥65 years



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3B
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Age
 Safety Population

TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Asthenia**
 ≥65 years




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3B
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Age
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders**
 ≥65 years




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3B
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Age
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders** and Preferred Term **Hypertension**
 ≥65 years




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3B
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Age
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Skin and subcutaneous tissue disorders**
 ≥65 years




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3C
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Sex
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions**
 Male



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3C
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Sex
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions**
 Male



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3C
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Sex
 Safety Population


TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 Male



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3C
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Sex
 Safety Population

TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Asthenia**
 Male




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3C
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Sex
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders**
 Male




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3C
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Sex
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders** and Preferred Term **Hypertension**
 Male



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3C
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Sex
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Skin and subcutaneous tissue disorders**
 Male



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3C
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Sex
 Safety Population

TEAE \geq CTCAE Grade 3 in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Palmar-plantar erythrodysesthesia syndrome**
 Male



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3C
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Sex
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions**
 Female



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3C
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Sex
 Safety Population


TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 Female



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3C
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Sex
 Safety Population

TEAE \geq CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Asthenia**
 Female




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3C
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Sex
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders**
 Female




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3C
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Sex
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders** and Preferred Term **Hypertension**
 Female




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3C
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Sex
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Skin and subcutaneous tissue disorders**
 Female




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3D
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Geographic Region
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions**
 North America



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3D
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Geographic Region
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions**
 North America



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3D
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Geographic Region
 Safety Population

TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 North America




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3D
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Geographic Region
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders**
 North America




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3D
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Geographic Region
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders** and Preferred Term **Hypertension**
 North America




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3D
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Geographic Region
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Skin and subcutaneous tissue disorders**
 North America




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3D
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Geographic Region
 Safety Population
 TEAE \geq CTCAE Grade 3 in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Palmar-plantar erythrodysesthesia syndrome**
 North America



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3D
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Geographic Region
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions**
 Europe



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3D
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Geographic Region
 Safety Population


TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 Europe



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3D
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Geographic Region
 Safety Population

TEAE \geq CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Asthenia**
 Europe




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3D
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Geographic Region
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders**
 Europe




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3D
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Geographic Region
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders** and Preferred Term **Hypertension**
 Europe




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3D
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Geographic Region
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Skin and subcutaneous tissue disorders**
 Europe




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3D
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Geographic Region
 Safety Population
 TEAE \geq CTCAE Grade 3 in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Palmar-plantar erythrodysesthesia syndrome**
 Europe



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3D
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Geographic Region
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions**
 Asia



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3D
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Geographic Region
 Safety Population

TEAE \geq CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 Asia




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3D
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Geographic Region
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders**
 Asia




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3D
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Geographic Region
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders** and Preferred Term **Hypertension**
 Asia




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3D
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Geographic Region
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Skin and subcutaneous tissue disorders**
 Asia




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3E
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by ECOG PS
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions**
 ECOG: 0



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3E
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by ECOG PS
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions**
 ECOG: 0



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3E
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by ECOG PS
 Safety Population


TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 ECOG: 0



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3E
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by ECOG PS
 Safety Population

TEAE \geq CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Asthenia**
 ECOG: 0




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3E
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by ECOG PS
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders**
 ECOG: 0




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3E
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by ECOG PS
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders** and Preferred Term **Hypertension**
 ECOG: 0



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3E
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by ECOG PS
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Skin and subcutaneous tissue disorders**
 ECOG: 0



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3E
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by ECOG PS
 Safety Population

TEAE \geq CTCAE Grade 3 in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Palmar-plantar erythrodysesthesia syndrome**
 ECOG: 0



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3E
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by ECOG PS
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions**
 ECOG: 1



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3E
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by ECOG PS
 Safety Population


TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 ECOG: 1



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3E
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by ECOG PS
 Safety Population

TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Asthenia**
 ECOG: 1




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3E
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by ECOG PS
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders**
 ECOG: 1




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3E
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by ECOG PS
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders** and Preferred Term **Hypertension**
 ECOG: 1




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3E
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by ECOG PS
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Skin and subcutaneous tissue disorders**
 ECOG: 1




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3F
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Duration of Metastatic Disease
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions**
 ≤ 18 months



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3F
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Duration of Metastatic Disease
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions**
 ≤ 18 months



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3F
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Duration of Metastatic Disease
 Safety Population

TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 ≤ 18 months




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3F
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Duration of Metastatic Disease
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders**
 ≤ 18 months




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3F
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Duration of Metastatic Disease
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders** and Preferred Term **Hypertension**
 ≤ 18 months



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3F
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Duration of Metastatic Disease
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Skin and subcutaneous tissue disorders**
 ≤ 18 months



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3F
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Duration of Metastatic Disease
 Safety Population

TEAE \geq CTCAE Grade 3 in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Palmar-plantar erythrodysesthesia syndrome**
 \leq 18 months



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3F
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Duration of Metastatic Disease
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions**
 > 18 months



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3F
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Duration of Metastatic Disease
 Safety Population


TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 > 18 months



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3F
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Duration of Metastatic Disease
 Safety Population

TEAE \geq CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Asthenia**
 > 18 months




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3F
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Duration of Metastatic Disease
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders**
 > 18 months




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3F
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Duration of Metastatic Disease
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders** and Preferred Term **Hypertension**
 > 18 months




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3F
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Duration of Metastatic Disease
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Skin and subcutaneous tissue disorders**
 > 18 months




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3G
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Primary Tumor Site at 1st Diagnosis
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions**
 Colon



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3G
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Primary Tumor Site at 1st Diagnosis
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions**
 Colon



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3G
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Primary Tumor Site at 1st Diagnosis
 Safety Population


TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 Colon



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3G
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Primary Tumor Site at 1st Diagnosis
 Safety Population

TEAE \geq CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Asthenia**
 Colon




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3G
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Primary Tumor Site at 1st Diagnosis
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders**
 Colon




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3G
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Primary Tumor Site at 1st Diagnosis
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders** and Preferred Term **Hypertension**
 Colon



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3G
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Primary Tumor Site at 1st Diagnosis
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Skin and subcutaneous tissue disorders**
 Colon



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3G
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Primary Tumor Site at 1st Diagnosis
 Safety Population

TEAE \geq CTCAE Grade 3 in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Palmar-plantar erythrodysesthesia syndrome**
 Colon



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3G
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Primary Tumor Site at 1st Diagnosis
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions**
 Rectum



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3G
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Primary Tumor Site at 1st Diagnosis
 Safety Population


TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 Rectum



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3G
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Primary Tumor Site at 1st Diagnosis
 Safety Population

TEAE \geq CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Asthenia**
 Rectum




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3G
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Primary Tumor Site at 1st Diagnosis
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders**
 Rectum




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3G
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Primary Tumor Site at 1st Diagnosis
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders** and Preferred Term **Hypertension**
 Rectum



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3G
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Primary Tumor Site at 1st Diagnosis
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Skin and subcutaneous tissue disorders**
 Rectum



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3G
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Primary Tumor Site at 1st Diagnosis
 Safety Population

TEAE \geq CTCAE Grade 3 in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Palmar-plantar erythrodysesthesia syndrome**
 Rectum




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3G
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Primary Tumor Site at 1st Diagnosis
 Safety Population
 TEAE \geq CTCAE Grade 3 in SOC Term **General disorders and administration site conditions**
 Colon and Rectum



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3G
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Primary Tumor Site at 1st Diagnosis
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 Colon and Rectum



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3G
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Primary Tumor Site at 1st Diagnosis
 Safety Population

TEAE \geq CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Asthenia**
 Colon and Rectum




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3G
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Primary Tumor Site at 1st Diagnosis
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders**
 Colon and Rectum




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3G
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Primary Tumor Site at 1st Diagnosis
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders** and Preferred Term **Hypertension**
 Colon and Rectum




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3G
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Primary Tumor Site at 1st Diagnosis
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Skin and subcutaneous tissue disorders**
 Colon and Rectum




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3H
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by RAS Status
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions**
 WT (Wild Type)




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3H
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by RAS Status
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions**
 WT (Wild Type)




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3H
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by RAS Status
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 WT (Wild Type)




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3H
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by RAS Status
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Asthenia**
 WT (Wild Type)




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3H
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by RAS Status
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders**
 WT (Wild Type)




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3H
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by RAS Status
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders** and Preferred Term **Hypertension**
 WT (Wild Type)




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3H
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by RAS Status
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Skin and subcutaneous tissue disorders**
 WT (Wild Type)




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3H
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by RAS Status
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Palmar-plantar erythrodysesthesia syndrome**
 WT (Wild Type)



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3H
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by RAS Status
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions**
 Mutant



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3H
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by RAS Status
 Safety Population


TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 Mutant



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3H
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by RAS Status
 Safety Population

TEAE \geq CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Asthenia**
 Mutant




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3H
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by RAS Status
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders**
 Mutant




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3H
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by RAS Status
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders** and Preferred Term **Hypertension**
 Mutant




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3H
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by RAS Status
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Skin and subcutaneous tissue disorders**
 Mutant




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3I
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by BRAF Status
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions**
 WT (Wild Type)




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3I
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by BRAF Status
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions**
 WT (Wild Type)




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3I
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by BRAF Status
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 WT (Wild Type)




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3I
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by BRAF Status
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Asthenia**
 WT (Wild Type)




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3I
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by BRAF Status
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders**
 WT (Wild Type)




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3I
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by BRAF Status
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders** and Preferred Term **Hypertension**
 WT (Wild Type)




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3I
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by BRAF Status
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Skin and subcutaneous tissue disorders**
 WT (Wild Type)




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3I
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by BRAF Status
 Safety Population
 TEAE \geq CTCAE Grade 3 in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Palmar-plantar erythrodysesthesia syndrome**
 WT (Wild Type)




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3I
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by BRAF Status
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions**
 V600 E Mutation




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3I
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by BRAF Status
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 V600 E Mutation




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3I
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by BRAF Status
 Safety Population
 TEAE \geq CTCAE Grade 3 in SOC Term **Vascular disorders**
 V600 E Mutation




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3I
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by BRAF Status
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders** and Preferred Term **Hypertension**
 V600 E Mutation




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3I
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by BRAF Status
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Skin and subcutaneous tissue disorders**
 V600 E Mutation




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3I
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by BRAF Status
 Safety Population
 TEAE \geq CTCAE Grade 3 in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Palmar-plantar erythrodysesthesia syndrome**
 V600 E Mutation



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3I
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by BRAF Status
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions**
 Other



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3I
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by BRAF Status
 Safety Population


TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 Other



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3I
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by BRAF Status
 Safety Population

TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Asthenia**
 Other




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3I
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by BRAF Status
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders**
 Other




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3I
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by BRAF Status
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders** and Preferred Term **Hypertension**
 Other




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3I
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by BRAF Status
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Skin and subcutaneous tissue disorders**
 Other




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3J
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions**
 ≤3



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3J
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions**
 ≤3



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3J
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines
 Safety Population

TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 ≤3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3J
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Asthenia**
 ≤3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3J
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders**
 ≤3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3J
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders** and Preferred Term **Hypertension**
 ≤3



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3J
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines
 Safety Population
 TEAE \geq CTCAE Grade 3 in SOC Term **Skin and subcutaneous tissue disorders**
 ≤ 3



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3J
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines
 Safety Population

TEAE \geq CTCAE Grade 3 in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Palmar-plantar erythrodysesthesia syndrome**
 ≤ 3



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3J
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions**
 >3



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3J
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines
 Safety Population

TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3J
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines
 Safety Population
 TEAE \geq CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Asthenia**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3J
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3J
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders** and Preferred Term **Hypertension**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3J
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Skin and subcutaneous tissue disorders**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions**
 ≤3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions**
 ≤3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 ≤3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE \geq CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Asthenia**
 ≤ 3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders**
 ≤3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders** and Preferred Term **Hypertension**
 ≤3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Skin and subcutaneous tissue disorders**
 ≤3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Palmar-plantar erythrodysesthesia syndrome**
 ≤3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE \geq CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Asthenia**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders** and Preferred Term **Hypertension**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3K
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Prior Chemotherapy Treatment Lines in Metastatic Disease
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Skin and subcutaneous tissue disorders**
 >3




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions**
 Yes



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions**
 Yes



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population


TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 Yes



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population

TEAE \geq CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Asthenia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders** and Preferred Term **Hypertension**
 Yes



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Skin and subcutaneous tissue disorders**
 Yes



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population

TEAE \geq CTCAE Grade 3 in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Palmar-plantar erythrodysesthesia syndrome**
 Yes



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE \geq CTCAE Grade 3 in SOC Term **General disorders and administration site conditions**
 No



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population


TEAE \geq CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 No



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population

TEAE \geq CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Asthenia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3L
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior VEGFi
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions**
 Yes



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions**
 Yes



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population


TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 Yes



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population

TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Asthenia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders** and Preferred Term **Hypertension**
 Yes



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Skin and subcutaneous tissue disorders**
 Yes



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population

TEAE \geq CTCAE Grade 3 in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Palmar-plantar erythrodysesthesia syndrome**
 Yes



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions**
 No



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population

TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 No




	Number of Patients at Risk																					
	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21
Placebo	142	135	96	35	21	10	6	2	2	1	1	1	1	0								
Fruquintinib	277	270	240	173	133	97	80	53	46	30	23	14	11	5	5	5	4	4	3	2	1	

BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population

TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Asthenia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders** and Preferred Term **Hypertension**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3M
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior EGFRi
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Skin and subcutaneous tissue disorders**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions**
 TAS-102



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions**
 TAS-102



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population


TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 TAS-102



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population

TEAE \geq CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Asthenia**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders** and Preferred Term **Hypertension**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Skin and subcutaneous tissue disorders**
 TAS-102




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE \geq CTCAE Grade 3 in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Palmar-plantar erythrodysesthesia syndrome**
 TAS-102



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regora fenib
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions**
 Regora fenib



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regora fenib
 Safety Population


TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 Regora fenib



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regora fenib
 Safety Population

TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Asthenia**
 Regora fenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regora fenib
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders**
 Regora fenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regora fenib
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders** and Preferred Term **Hypertension**
 Regora fenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Skin and subcutaneous tissue disorders**
 Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Palmar-plantar erythrodysesthesia syndrome**
 Regorafenib



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions**
 TAS-102 and Regorafenib



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population


TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 TAS-102 and Regorafenib



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population

TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Asthenia**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders** and Preferred Term **Hypertension**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3N
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior TAS-102 and/or Regorafenib
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Skin and subcutaneous tissue disorders**
 TAS-102 and Regorafenib




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions**
 Yes



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions**
 Yes



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population


TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 Yes



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population

TEAE \geq CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Asthenia**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders** and Preferred Term **Hypertension**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Skin and subcutaneous tissue disorders**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Palmar-plantar erythrodysesthesia syndrome**
 Yes



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions**
 No



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population


TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 No



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population

TEAE \geq CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Asthenia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders** and Preferred Term **Hypertension**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3O
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Liver Metastases
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Skin and subcutaneous tissue disorders**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders** and Preferred Term **Hypertension**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Skin and subcutaneous tissue disorders**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE \geq CTCAE Grade 3 in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Palmar-plantar erythrodysesthesia syndrome**
 Yes




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Asthenia**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders** and Preferred Term **Hypertension**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3P
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Prior Treatment with Immune Checkpoint Inhibitors for MSI-H/dMMR
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Skin and subcutaneous tissue disorders**
 No




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE \geq CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Asthenia**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders** and Preferred Term **Hypertension**
 Single



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Skin and subcutaneous tissue disorders**
 Single



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population

TEAE ≥ CTCAE Grade 3 in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Palmar-plantar erythrodysesthesia syndrome**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE \geq CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Asthenia**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders** and Preferred Term **Hypertension**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3Q
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites Other than Colon or Rectum
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Skin and subcutaneous tissue disorders**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE \geq CTCAE Grade 3 in SOC Term **General disorders and administration site conditions**
 Single



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions**
 Single



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population


TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 Single



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population

TEAE \geq CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Asthenia**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders**
 Single




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders** and Preferred Term **Hypertension**
 Single



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Skin and subcutaneous tissue disorders**
 Single



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population

TEAE \geq CTCAE Grade 3 in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Palmar-plantar erythrodysesthesia syndrome**
 Single



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions**
 Multiple



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population


TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 Multiple



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population

TEAE \geq CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Asthenia**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders** and Preferred Term **Hypertension**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3R
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Number of Metastatic Tumor Sites
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Skin and subcutaneous tissue disorders**
 Multiple




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions**
 < 18.5



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions**
 < 18.5



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population


TEAE \geq CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 < 18.5



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population

TEAE \geq CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Asthenia**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE \geq CTCAE Grade 3 in SOC Term **Vascular disorders**
 < 18.5




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders** and Preferred Term **Hypertension**
 < 18.5



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Skin and subcutaneous tissue disorders**
 < 18.5



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population

TEAE \geq CTCAE Grade 3 in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Palmar-plantar erythrodysesthesia syndrome** < 18.5



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions**
 ≥ 18.5 to < 24



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population

TEAE \geq CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE \geq CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Asthenia**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders**
 ≥ 18.5 to < 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders** and Preferred Term **Hypertension**
 ≥ 18.5 to < 24



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Skin and subcutaneous tissue disorders**
 ≥ 18.5 to < 24



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population

TEAE \geq CTCAE Grade 3 in SOC Term **Skin and subcutaneous tissue disorders** and Preferred Term **Palmar-plantar erythrodysesthesia syndrome**
 ≥ 18.5 to < 24



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **General disorders and administration site conditions**
 ≥ 24



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population

TEAE \geq CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Disease progression**
 ≥ 24




	Number of Patients at Risk																					
	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21
Placebo	135	128	98	40	17	9	4	1	1	1	1	1	1	0								
Fruquintinib	285	282	252	193	147	109	94	62	53	32	22	14	11	5	5	5	5	4	3	2	1	

BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.


Figure 35.1.1.6.5.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population

TEAE \geq CTCAE Grade 3 in SOC Term **General disorders and administration site conditions** and Preferred Term **Asthenia**
 ≥ 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders**
 ≥ 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Vascular disorders** and Preferred Term **Hypertension**
 ≥ 24




BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.

Figure 35.1.1.6.5.3S
 Kaplan-Meier Plot for Time to Onset of TEAE by SOC/PT by Body Mass Index
 Safety Population
 TEAE ≥ CTCAE Grade 3 in SOC Term **Skin and subcutaneous tissue disorders**
 ≥ 24



BSC=Best supportive care, TEAE=Treatment Emergent Adverse Event.



	Number of Patients at Risk																					
	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21
Placebo	135	130	98	40	17	9	4	1	1	1	1	1	1	0								
Fruquintinib	285	277	243	180	134	97	81	54	47	26	19	11	8	4	4	4	4	3	3	2	1	